MBX Biosciences Announces IND Submission Of MBX 4291, Its Long-Acting GLP1/GIP Receptor Co-Agonist Prodrug For The Treatment Of Obesity
June 16 (Reuters) - MBX Biosciences Inc MBX.O:
MBX BIOSCIENCES ANNOUNCES IND SUBMISSION OF MBX 4291, ITS LONG-ACTING GLP1/GIP RECEPTOR CO-AGONIST PRODRUG FOR THE TREATMENT OF OBESITY
MBX BIOSCIENCES INC - PHASE 1 TRIAL OF MBX 4291 EXPECTED TO INITIATE IN Q3 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Is Meta Platforms Stock a Smart Buy Ahead of Q1 2026 Earnings? Unpacking AI Growth and Investment Potential

Tradingkey






